Total Funding
54
62
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
100928
Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Bruce D. Steel: Co-founder, Director, and President and Chief Executive OfficerPast Role: Anaphore, Chief Business Officer
Krishna Polu: Chief Medical OfficerPast Role: CytomX Therapeutics, Chief Medical Officer
About the Company
Equillium Inc is a biotechnology company that develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with an unmet medical need. Its primary product candidate is EQ001, which is a clinical-stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role
in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis.
